INSTITUTE OF BIOMED RESH - MRES STOCK NEWS

M2Bio Food and Beverage, a division of The Institute of Biomedical Research Corp. (OTC PINK:MRES), has announced a strategic shift away from CBD-infused food products. The company cites complex scientific and regulatory challenges associated with CBD as the primary reasons for this decision. Instead, M2Bio will focus on expanding its core offerings, particularly the Liviana® product line, known for premium, organic ingredients.

This pivot is expected to streamline operations and open up broader distribution opportunities, especially in international markets where CBD restrictions have been a barrier. While discontinuing CBD in food products, the company will continue exploring CBD's potential in topical applications for pets with skin conditions. This strategic move aims to enhance value for customers, partners, and shareholders by focusing on areas where M2Bio can more reliably control and optimize health benefits.

Institute of Biomedical Research Corp. (MRES) announces stellar growth in 2023 with the M2Bio Food and Beverage division. The company expanded its product range, entered new markets, and formed strategic partnerships, setting the stage for further expansion in 2024.

In March 2024, the Institute of Biomedical Research Corporation (MRES) finalized the sale of 100% ownership of M2MMA to Real American Capital Corporation (RLAB) through a share-based settlement. MRES is projected to hold approximately 71% of RLAB's fully diluted shares, with 56,368,000 outstanding shares. MRES's CEO and CFO have been appointed as Chairman and CFO of RLAB. MRES also disclosed collaborations with Innovative Holdings Alliance Inc. for distribution in the USA and the University of Pretoria for AI-driven phytomedicine research.

M2Bio Sciences launches M2BioKids, a pioneering division dedicated to enhancing mental and physical health in children aged five and under. M2BioKids focuses on nutritional science, physical development, and mental/cognitive enhancement through innovative AI-driven solutions. The initiative aims to revolutionize early childhood development, addressing global undernutrition challenges and offering evidence-based solutions for optimal growth and health. CEO Jeff Robinson emphasizes the commitment to leveraging AI and biotechnological innovations to create a healthier, more intellectually capable generation.

Institute of Biomedical Research Corp. (MRES) announces M2Enviro updates focusing on mycelium technology and sustainable packaging solutions. The company achieved breakthroughs in 2023 with Hempcelium™, a biodegradable packaging solution. M2Enviro plans to expand its operations in 2024 with a strong emphasis on research & development and the advancement of Hempcelium™. The company aims to meet the growing demand for its eco-friendly products through the construction of a new production facility and targeted marketing campaigns.

Institute of Biomedical Research Corp. announces updates for its M2Biome division, focusing on nutraceutical biotechnology, plant-based cannabinoids, and mental health research. The division achieved significant growth in 2023, launching a website, providing nutritional information, recipes, and educational content. They plan to delve deeper into gut health in 2024 and develop products like premium black garlic and nutritional bars. The division aims to revolutionize nutrition with AI-driven personalized nutrition recommendations and a groundbreaking M2Biome App in 2024.

Real American Capital Corporation (RLAB) has acquired 100% ownership of the concept, business model, contacts, and contracts from Institute of Biomedical Research Corporation (MRES) to establish a mixed martial arts league called 'M2MMA'. The transaction will be settled entirely in shares, resulting in a change of control of RLAB. Jeff Robinson and Willem Jonker, CEO and CFO of MRES, have been appointed Chairman and Chief Financial Officer of RLAB. Doug Newton, outgoing co-CEO of RLAB, has a lifelong connection to martial arts and supports the exciting innovations Jeff and his team are bringing to the sport.

Institute of Biomedical Research Corp. (MRES) announces M2MMA division's international expansion in 2024, highlighting its achievements in 2023 and the appointment of Chris Cannon as General Manager. The company is focused on global promotions, new partnerships, and maintaining a health-focused approach in the sports community.

Institute of Biomedical Research Corp. (MRES): M2Bio Sciences Expands into Dubai Science Park, positioning itself at the forefront of global biotechnology and fintech. The company's strategic move reflects a commitment to fostering collaboration and innovation in the international landscape of nutraceutical biotechnology and AI-driven research.